We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals

60 hedge funds and large institutions have $57M invested in Tonix Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 5

156% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 9

74% more call options, than puts

Call options by funds: $951K | Put options by funds: $548K

28% more funds holding

Funds holding: 4760 (+13)

14% more capital invested

Capital invested by funds: $50M → $57M (+$6.93M)

8% more ownership

Funds ownership: 18.9%26.9% (+8%)

Holders
60
Holders Change
+13
Holders Change %
+27.66%
% of All Funds
0.79%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
23
Reduced
9
Closed
5
Calls
$951K
Puts
$548K
Net Calls
+$403K
Net Calls Change
+$403K

TNXP Hedge Fund Activity: Q3 2025 in Review

60 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q3 2025, worth a combined $57M — up 14% from $50M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new TNXP positions and 5 closed out — a net gain of 13 holders — while 23 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $14.6M. The largest seller was Nuveen, cutting an estimated $1.36M.

  • 60 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q3 2025, up from 47 in Q2 2025.
  • Funds reported $57M of Tonix Pharmaceuticals stock for Q3 2025, up 14% quarter-over-quarter.
  • 18 funds opened new Tonix Pharmaceuticals positions in Q3 2025 and 5 closed out, a net change of +13 holders.
  • The largest Tonix Pharmaceuticals buyer in Q3 2025 was Vanguard Group, an estimated $14.6M added.
  • The largest Tonix Pharmaceuticals seller in Q3 2025 was Nuveen, an estimated $1.36M sold.

Based on aggregated 13F filings for Q3 2025.